GURUFOCUS.COM » STOCK LIST » USA » NAS » VistaGen Therapeutics Inc (NAS:VTGN) » Definitions » Additional Paid-In Capital
Switch to:

VistaGen Therapeutics Additional Paid-In Capital

: $336.08 Mil(As of Mar. 2022)
View and export this data going back to 2011. Start your Free Trial

VistaGen Therapeutics's quarterly additional paid-in capital increased from Sep. 2021 ($324.81 Mil) to Dec. 2021 ($334.66 Mil) and increased from Dec. 2021 ($334.66 Mil) to Mar. 2022 ($336.08 Mil).

VistaGen Therapeutics's annual additional paid-in capital increased from Mar. 2020 ($200.09 Mil) to Mar. 2021 ($315.60 Mil) and increased from Mar. 2021 ($315.60 Mil) to Mar. 2022 ($336.08 Mil).


VistaGen Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for VistaGen Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VistaGen Therapeutics Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Additional Paid-In Capital
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 167.40 192.13 200.09 315.60 336.08

VistaGen Therapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Additional Paid-In Capital Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 315.60 316.98 324.81 334.66 336.08

VistaGen Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

VistaGen Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


VistaGen Therapeutics Business Description

VistaGen Therapeutics logo
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
Adler Reid G. officer: CHIEF LEGAL OFFICER C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94090
Fitzpatrick Margaret M director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94080
Rotunno Mary L. director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE. SOUTH SAN FRANCISCO CA 94090
Curley Joanne director C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Ginski Mark J officer: SENIOR VP, HEAD OF CMC 12119 CECILIA CT KINGSVILLE MD 21087
Cunningham Ann Michelle director 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Mcpartland Mark A. officer: VP Corporate Development C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan officer: CHIEF MEDICAL OFFICER 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B director 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Dotson Jerrold Duane officer: ACTING CFO 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Underdown Brian J. director C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Bonfiglio Gregory A. director 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Rice A. Franklin officer: CHIEF FINANCIAL OFFICER 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Cato Allen Easley 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713

VistaGen Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)